Cityclinic Przychodnia Lekarsko-Psychologiczna Matusiak sp.p.
- Address
- lock Available on a paid plan
Cityclinic Przychodnia Lekarsko-Psychologiczna Matusiak sp.p. - Advanced Dermatology Research Center
Cityclinic Przychodnia Lekarsko-Psychologiczna Matusiak sp.p. is a specialized dermatology research facility with extensive expertise in investigating novel therapeutic approaches for complex inflammatory skin conditions. The center demonstrates particular strength in conducting Phase 2 through Phase 4 clinical trials for chronic, difficult-to-treat dermatological disorders, contributing valuable data on both biologic and small molecule therapeutics.
- Chronic inflammatory skin disorders including moderate-to-severe plaque psoriasis, hidradenitis suppurativa, and atopic dermatitis
- Autoimmune and rare dermatological conditions such as bullous pemphigoid, cutaneous lupus erythematosus, pyoderma gangrenosum, and prurigo nodularis
- Hair and scalp disorders including alopecia areata across pediatric and adult populations
- Urticaria and pruritic conditions including chronic spontaneous urticaria and chronic pruritus of unknown origin
The research center's comprehensive portfolio encompasses studies evaluating JAK inhibitors, IL-17 inhibitors, IL-23 inhibitors, anti-IgE therapies, and other innovative immunomodulatory agents. With significant experience in long-term extension studies and pediatric populations, Cityclinic demonstrates capability in assessing both short-term efficacy and sustained safety profiles. The facility's expertise extends to evaluating topical formulations for conditions like actinic keratosis and palmoplantar pustulosis, as well as investigating emerging biologics for previously treatment-refractory conditions, positioning it as a vital contributor to advancing dermatological therapeutics.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 therapeutic areas and 15 of 57 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 55 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 14 by active trials.
- 1Almirall S.A.3active
lock +13 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Almirall S.A.6trials
lock +15 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Cityclinic Przychodnia Lekarsko-Psychologiczna Matusiak sp.p.
lock Showing 1 of 71 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A 2-year Open-label Extension Study to Assess the Long-term Safety and Efficacy of Lebrikizumab in Adult and Adolescent Patients with Moderate-to-Severe Atopic Dermatitis | Almirall S.A. | Phase III | Not Recruiting | May 2023 | Apr 2026 |
IMP list
lock Showing 1 of 57 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Zasocitinib | 5 | Unknown | 2024-04-04 | 2026-04-28 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.